Effect of a chronic GSM 900 MHz exposure on glia in the rat brain.

Biomed Pharmacother

Unité de Toxicologie Expérimentale, INERIS, Parc technologique ALATA, BP2, 60550 Verneuil-en-Halatte, France.

Published: August 2008

Extension of the mobile phone technology raises concern about the health effects of 900 MHz microwaves on the central nervous system (CNS). In this study we measured GFAP expression using immunocytochemistry method, to evaluate glial evolution 10 days after a chronic exposure (5 days a week for 24 weeks) to GSM signal for 45 min/day at a brain-averaged specific absorption rate (SAR)=1.5 W/kg and for 15 min/day at a SAR=6 W/kg in the following rat brain areas: prefrontal cortex (PfCx), caudate putamen (Cpu), lateral globus pallidus of striatum (LGP), dentate gyrus of hippocampus (DG) and cerebellum cortex (CCx). In comparison to sham or cage control animals, rats exposed to chronic GSM signal at 6 W/kg have increased GFAP stained surface areas in the brain (p<0.05). But the chronic exposure to GSM at 1.5 W/kg did not increase GFAP expression. Our results indicated that chronic exposure to GSM 900 MHz microwaves (SAR=6 W/kg) may induce persistent astroglia activation in the rat brain (sign of a potential gliosis).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2008.03.002DOI Listing

Publication Analysis

Top Keywords

chronic gsm
8
900 mhz
8
rat brain
8
gsm signal
8
gsm 900
4
mhz exposure
4
exposure glia
4
glia rat
4
brain extension
4
extension mobile
4

Similar Publications

Chronic Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), affecting the female genital tract in 25-66% of the patients. This condition, referred to as Genital GVHD is an underdiagnosed gynecologic comorbidity, that can significantly impair quality of life. We aimed to describe the prevalence and management of genital GVHD following HSCT.

View Article and Find Full Text PDF

The Secretin receptor (SCTR) presents a promising path for hypertension management, with KSD179019 as identified as a Positive Allosteric Modulator (PAM) of SCTR, demonstrating anti-hypertensive effects in animal models. Our objective was to comprehensively evaluate the potential toxicity of KSD179019 through in vitro and in vivo investigations. Initial in vitro studies showed minimal toxicity in liver and kidney cells and non-mutagenicity in bacterial assays.

View Article and Find Full Text PDF

Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms.

Int J Womens Health

November 2024

Jessop Wing, Tree Root Walk, Sheffield, S10 2SF, UK.

Genitourinary syndrome of the menopause (GSM) is a chronic, often progressive condition, characterised by symptoms relating to oestrogen deficiency including; vaginal dryness, burning, itching, dyspareunia, dysuria, urinary urgency and recurrent urinary tract infections. GSM affects up to 70% of breast cancer survivors with a tendency to particularly severe symptoms, owing to the effects of iatrogenic menopause and endocrine therapy. Patients and clinicians can be reluctant to replace oestrogen vaginally due to fear of cancer recurrence.

View Article and Find Full Text PDF

Schizophrenia is a complex psychotic disorder characterized by positive symptoms, such as hallucinations and delusions, and negative symptoms, including emotional withdrawal and apathy. Its profound impact on an individual's functioning requires meticulous and sustained management, typically through the use of antipsychotic medications. While these treatments aim to alleviate symptoms and improve quality of life, long-term therapy often necessitates careful balancing to mitigate potential side effects.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the efficacy of the MVA-BN-RSV vaccine, designed for older adults (≥60 years), against respiratory disease caused by RSV during the 2022-2023 season, involving 18,348 participants who received either the vaccine or a placebo.
  • - Vaccine efficacy was reported as 42.9% against RSV-associated lower respiratory tract disease (LRTD) with 3 symptoms and 59.0% against LRTD with 2 symptoms; however, the primary endpoint was not met due to the lower confidence interval being below a predetermined success criterion.
  • - The vaccine demonstrated mild to moderate side effects, showed promise by confirming immunogenicity (increased antibody responses), but provided
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!